Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

DuBois, Steven G; Marachelian, Araz; Fox, Elizabeth; Kudgus, Rachel A; Reid, Joel M; Groshen, Susan; Malvar, Jemily; Bagatell, Rochelle; Wagner, Lars; Maris, John M; Hawkins, Randall; Courtier, Jesse; Lai, Hollie; Goodarzian, Fariba; Shimada, Hiroyuki; Czarnecki, Scarlett; Tsao-Wei, Denice; Matthay, Katherine K; Mosse, Yael P

DuBois, Steven G; Marachelian, Araz; Fox, Elizabeth; Kudgus, Rachel A; Reid, Joel M; Groshen, Susan; Malvar, Jemily; Bagatell, Rochelle; Wagner, Lars; Maris, John M; Hawkins, Randall; Courtier, Jesse; Lai, Hollie; Goodarzian, Fariba; Shimada, Hiroyuki; Czarnecki, Scarlett; Tsao-Wei, Denice; Matthay, Katherine K; Mosse, Yael P.

Afiliación

DuBois SG; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Marachelian A; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Fox E; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Kudgus RA; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Reid JM; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Groshen S; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Malvar J; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Bagatell R; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Wagner L; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Maris JM; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Hawkins R; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Courtier J; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Lai H; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Goodarzian F; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Shimada H; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Czarnecki S; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Tsao-Wei D; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Matthay KK; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S
Mosse YP; Steven G. DuBois, Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA; Araz Marachelian, Susan Groshen, Jemily Malvar, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, and Denice Tsao-Wei, University of Southern California Keck S

J Clin Oncol ; 34(12): 1368-75, 2016 Apr 20.

Article en En | MEDLINE | ID: mdl-26884555

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Aurora Quinasa A/antagonistas & inhibidores; Azepinas/administración & dosificación; Camptotecina/análogos & derivados; Dacarbazina/análogos & derivados; Neuroblastoma/tratamiento farmacológico; Inhibidores de Proteínas Quinasas/administración & dosificación; Pirimidinas/administración & dosificación; Administración Oral; Adolescente; Adulto; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos; Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética; Aurora Quinasa A/metabolismo; Azepinas/efectos adversos; Azepinas/farmacocinética; Camptotecina/administración & dosificación; Camptotecina/efectos adversos; Camptotecina/farmacocinética; Niño; Preescolar; Dacarbazina/administración & dosificación; Dacarbazina/efectos adversos; Progresión de la Enfermedad; Supervivencia sin Enfermedad; Esquema de Medicación; Resistencia a Antineoplásicos; Femenino; Genotipo; Glucuronosiltransferasa/genética; Glucuronosiltransferasa/metabolismo; Humanos; Lactante; Irinotecán; Estimación de Kaplan-Meier; Masculino; Dosis Máxima Tolerada; Recurrencia Local de Neoplasia; Neuroblastoma/enzimología; Neuroblastoma/mortalidad; Neuroblastoma/patología; Fenotipo; Inhibidores de Proteínas Quinasas/efectos adversos; Inhibidores de Proteínas Quinasas/farmacocinética; Pirimidinas/efectos adversos; Pirimidinas/farmacocinética; Comprimidos; Temozolomida; Factores de Tiempo; Resultado del Tratamiento; Estados Unidos; Adulto Joven

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Azepinas / Camptotecina / Protocolos de Quimioterapia Combinada Antineoplásica / Dacarbazina / Inhibidores de Proteínas Quinasas / Aurora Quinasa A / Neuroblastoma Tipo de estudio: Clinical_trials País/Región como asunto: America do norte Idioma: En Revista: J Clin Oncol Año: 2016 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google